Last reviewed · How we verify
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted is a Biologic drug developed by International AIDS Vaccine Initiative. It is currently in Phase 1 development.
At a glance
| Generic name | BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted |
|---|---|
| Sponsor | International AIDS Vaccine Initiative |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted CI brief — competitive landscape report
- BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted updates RSS · CI watch RSS
- International AIDS Vaccine Initiative portfolio CI
Frequently asked questions about BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
What is BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted?
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted is a Biologic drug developed by International AIDS Vaccine Initiative.
Who makes BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted?
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted is developed by International AIDS Vaccine Initiative (see full International AIDS Vaccine Initiative pipeline at /company/international-aids-vaccine-initiative).
What development phase is BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted in?
BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted is in Phase 1.